Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues.

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

Why COMPASS Pathways is Back on Investors’ Radar Interest in COMPASS Pathways (NasdaqGS:CMPS) has picked up after a White House executive order aimed at accelerating medical treatments for serious ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug ...

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Compass Pathways may be the first to benefit from an accelerated approval process.

The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...